14. Palumbo A, Bringh<strong>en</strong> S, Caravita T, et al. Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomi<strong>de</strong> compared with melphalan and prednisone alone in el<strong>de</strong>rly pati<strong>en</strong>ts with multiple myeloma: randomised controlled trial. Lancet 2006;11: 825-31 15. Palumbo A, Bringh<strong>en</strong> S, Cavalli M et al. Bortezomib, Melphalan, Prednisone and Thalidomi<strong>de</strong> Followed by Maint<strong>en</strong>ance with Bortezomib and Thalidomi<strong>de</strong> (VMPT-VT) for Initial Treatm<strong>en</strong>t of El<strong>de</strong>rly Multiple Myeloma Pati<strong>en</strong>ts: Updated Follow-up and Impact of Prognostic Factors. Blood 2010; 116 (abst. 620) 16. Palumbo A, Z<strong>de</strong>nek A, Kropff et al. A phase 3 study evaluating the efficacy and safety of l<strong>en</strong>alidomi<strong>de</strong> combined melphalan and prednisone followed by continous l<strong>en</strong>alidomi<strong>de</strong> maint<strong>en</strong>ance (MPR-R) in pati<strong>en</strong>ts ≥ 65 years with newly diagnosed multiple myeloma: Update results for aged 65-75 years <strong>en</strong>rolled in MM-015. Blood 2011; 118 (abst.475) 17. Palumbo A, An<strong>de</strong>rson K. Multiple Myeloma. N Engl J Med 2011; 364: 1046-60 18. Palumbo A, Bringh<strong>en</strong> S, Ludwig H et al. Personalized therapy in multiple myeloma according to pati<strong>en</strong>t age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011; 118: 4519-4529 19. Pönisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A, Freund M, Pasold R, Friedrich T, Helbig W, Nie<strong>de</strong>rwieser D. Treatm<strong>en</strong>t of b<strong>en</strong>damustine and prednisone in pati<strong>en</strong>ts with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatm<strong>en</strong>t failure and improved quality of life compared to treatm<strong>en</strong>t with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006; 132(4):205-12 20. Rajkumar SV, Jacobus S, Callan<strong>de</strong>r N et al. L<strong>en</strong>alidomi<strong>de</strong> plus high dose <strong>de</strong>xametasona vs l<strong>en</strong>alidomi<strong>de</strong> plus low dose <strong>de</strong>xametasona as initial therapy for newly diagnosed multiple myeloma: an oplel-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37 21. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, An<strong>de</strong>rson KC, Esseltine DL, Liu K, Cakana A, van <strong>de</strong> Vel<strong>de</strong> H, Richardson PG; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatm<strong>en</strong>t of multiple myeloma. N Engl J Med. 2008; 359(9):906-17 22. San Miguel JM, Schlag R, Khuageva N et al. VMP vs MP in pati<strong>en</strong>ts with previously untreated multiple myeloma and no increased risk of second primary malignancies: Final results of the phase 3 VISTA trial. Blood 2011; 118 (abst.476) 23. Vesole DH, Jacobus S, Rajkumar SV et al. L<strong>en</strong>alidomi<strong>de</strong> plus lose doses <strong>de</strong>xametasone superior one and two year survival regardless of age compared to l<strong>en</strong>alidomi<strong>de</strong> plus highdoses <strong>de</strong>xametasone. Blood 2010; 116. (abst. 308) 24. Wijermans, Schaafsma M, van Nor<strong>de</strong>n Y, Ammerlaan R, Wittebol S, Sinnige H el al. Melphalan+prednisone versus Melphalan+prednisone+thalidomi<strong>de</strong> in induction therapy for multiple myeloma in el<strong>de</strong>rly pati<strong>en</strong>ts: Final analysis of the Dutch cooperative Group HOVON 49 study. Blood 2008; 112 (abst.649) Grupo Asturiano <strong>de</strong> Linfoma y <strong>Mieloma</strong> 54
Capítulo 6. TRATAMIENTO DE MIELOMA EN RECAIDA O REFRACTARIO - Definición <strong>de</strong> mieloma <strong>en</strong> recaída/refractario (MMRR) - Esquemas <strong>de</strong> rescate basados <strong>en</strong> IMIDS: L<strong>en</strong>alidomida <strong>de</strong>xametasona (RD) - Esquemas <strong>de</strong> rescate con Bortezomib (V) - Estrategias <strong>en</strong> recaída - Estrategias <strong>en</strong> mielomas refractarios - Situaciones especiales <strong>de</strong> recaída - Tratami<strong>en</strong>to con nuevas drogas <strong>en</strong> MMRR - Algoritmo <strong>de</strong> tratami<strong>en</strong>to <strong>en</strong> MMRR - Anexo 1: Sobre manejo <strong>de</strong> L<strong>en</strong>alidomida - Esquemas <strong>de</strong> tratami<strong>en</strong>to Dr Páyer (HUCA. Oviedo) Fecha: Abril 2012 Grupo Asturiano <strong>de</strong> Linfoma y <strong>Mieloma</strong> 55